Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.
During my research career, I became interested in different proteins involved in pathophysiological processes. Amongst them, the CD146 molecule, on which my team has worked for many years, is particularly exciting because it is both yin and yang, with involvement in many physiological processes such as angiogenesis or embryo implantation and, at the same time, a deleterious effect when expressed on tumour cells.
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team. To achieve this, we combine multiple and cross-cutting approaches from genes to proteins, from animal model cell tissue to humans, and from fundamental research to clinical application. This requires the use of advanced technology from transcriptomics proteomics, through imagery and the generation of antibodies. Marseille Immunopole is an extraordinary melting pot that allows us to work with many experts and combine these different approaches, with the common goal to bring new tests and new drugs for the benefit of patients.#recherche
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
AMU, IPC, CRCM
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
AMU, AP-HM, CIML